Coronavirus Notebook: EMA Issues New COVID-19 Vaccine Safety Updates, Australia Assesses Comirnaty In Younger Children
Executive Summary
The European regulator has warned of the risk of myocarditis, pericarditis and anaphylaxis with Novavax’s COVID-19 vaccine, Nuvaxovid, while Switzerland has updated its guidance on the use of COVID-19 medicines against virus variants. Iconovo has received funding to develop its ICOone nasal inhaler for use in pandemics in resource-poor settings.
You may also be interested in...
Coronavirus Notebook: Australia To Assess Omicron-Adapted Vaccine Riltozinameran, EU Advises On Boosters For Older & Vulnerable People
The EMA has drawn up a list of groups of critical medicines for use in health emergencies, while the European Parliament’s special COVID-19 committee is to discuss vaccination campaigns and challenges with the chiefs of the ECDC and HERA.
Coronavirus Notebook: Bivalent Spikevax OKd For Filing In Australia, Pfizer & Moderna Under Growing Pressure To Share mRNA Knowhow
The World Health Organization and UNICEF say that disruptions caused by COVID-19 and actions taken to tackle the pandemic have left many children without protection against measles and other diseases. Austria’s Apeiron has given an update on the development of its candidate therapeutic, APN01.
EU Boosts COVID-19 Vaccine Supplies With Moderna & HIPRA Deals
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”